STOCK TITAN

Avalo Therapeutics, Inc. - $AVTX STOCK NEWS

Welcome to our dedicated page for Avalo Therapeutics news (Ticker: $AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avalo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avalo Therapeutics's position in the market.

Rhea-AI Summary
Avalo Therapeutics, Inc. (AVTX) announced that AVTX-002 did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, but significantly reduced serum LIGHT levels. The company had approximately $6.3 million in cash as of June 30, 2023. The business is considering out-licensing or selling non-core assets to reduce expenses and is evaluating the potential sale of AVTX-801, AVTX-802, and AVTX-803. AVTX-002 showed promise in other inflammatory diseases, and AVTX-008 has potential in treating autoimmune diseases. The company had a net loss of $8.2 million for the second quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
-
Rhea-AI Summary
Avalo Therapeutics, Inc. (Nasdaq: AVTX) CEO and Chairman, Garry A. Neil, M.D., will participate in the SVB Securities Therapeutics Forum on July 11th-12th, 2023 in New York, NY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
-
Rhea-AI Summary
Avalo Therapeutics announced topline results from a Phase 2 trial evaluating AVTX-002 in patients with non-eosinophilic asthma. The trial did not meet its primary endpoint, but positive trends were observed in a sub-population of patients with elevated LIGHT levels. AVTX-002 demonstrated a favorable safety profile. Further analyses are ongoing to inform future studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-88.69%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.79%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.8%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.47%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
Avalo Therapeutics, Inc.

Nasdaq:AVTX

AVTX Rankings

AVTX Stock Data

15.92M
919.32k
0.09%
6.33%
7.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ROCKVILLE

About AVTX

cerecor inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. we are a delaware corporation, organized in april 2011 in partnership with various laboratories and research institutes at johns hopkins medical institute ("jhmi"). cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. we acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.